Please assess the completion status of the following clinical trial:

Trial Title: NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of inherited or acquired severe aplastic anemia (SAA)~* One of the following available donors:~  1. HLA-haploidentical relative~ 2. If recipient is \>= 40 years old, may use HLA-matched related donor~ 3. For recipients with inherited bone marrow failure syndromes (IBMFS) with clear evidence of same disorder in potential related donors, may use 10/10 matched unrelated donor~* Recipient and/or legal guardian must sign protocol informed consent~* Donor must be willing to donate bone marrow~* Left ventricular ejection fraction (LVEF) \>= 40%. For recipients \< 13 years old, shortening fraction \>= 26% may be used instead.~* Bilirubin \< 3 x upper limit of normal (ULN) for age, unless patient has Gilbert's disease~* aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5 x ULN for age~* For patients \>= 13 years old: estimated creatinine clearance \> 50 mL/min using Cockcroft-Gault formula and actual body weight~* For patients \>= 1 but \< 13 years old: glomerular filtration rate (GFR) estimated by updated Schwartz formula \>= 90 mL/min/1.73 m\^2. If estimated GFR is \< 90 mL/min/1.73 m\^2, 24-hour measured creatinine clearance must be \> 50 mL/min/1.73 m\^2.~* For patients \>= 8 years old, diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) \> 40%; forced expiratory volume at one second (FEV1) \> 50%; forced vital capacity (FVC) \> 50%~* For patients \< 8 years old or unable to undergo pulmonary function testing: no evidence of dyspnea at rest; no need for supplemental oxygen; oxygen saturation \> 92% on room air~* Karnofsky/Lansky status (depending on age) \>= 70%~* Females and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time. If unwilling, they must agree to complete abstinence.~Exclusion Criteria:~* Previous administration of immunosuppressive therapy for SAA.~* Fanconi anemia. At minimum, this diagnosis must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow in patients \< 30 years old.~* Clonal cytogenetic abnormalities consistent with pre-myelodysplastic syndrome (pre-MDS) or MDS on bone marrow examination~* Presence of anti-donor antibodies~* Prior allogeneic stem cell transplant~* Prior solid organ transplant~* Uncontrolled bacterial, viral, or fungal infection~* HIV seropositivity~* Active hepatitis B or C infection determined by serology and/or nucleic acid testing (NAT)~* Pregnancy or active breastfeeding~* Prior malignancies except: resected basal carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent \> 5 years previously. Other prior cancers will not be allowed unless approved by the PI.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bone marrow transplant (Type: EXPERIMENTAL): Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).